
CEL-SCI Closes $5.7M At-The-Market Stock Offering Under NYSE American Guidelines
CEL-SCI Secures $5.7 Million in At-the-Market Equity Offering to Advance Cancer Immunotherapy Program CEL-SCI Corporation (NYSE American: CVM), a clinical-stage biotechnology company dedicated to developing cancer immunotherapy treatments, has successfully closed a best-efforts equity offering that generated approximately $5.7 million…